drugset / Trial / NCT01127451
Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether participants with Stage IIIC and Stage IV Melanoma experience benefit when treated with Denileukin diftitox in two different dosing schedules.
Timeline
- Start
- 2010-06-22
- Primary completion
- 2015-04-07
- Completion
- 2015-04-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | denileukin diftitox | Protein / enzyme biologic | 12 ug/kg | Intravenous |